Skip to main content

Remote Job Finders (RJF)

Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.

Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.
Scroll to top